RESUMO
We conducted clinical and economic analysis of the protease inhibitor simeprevir versus currently available in Russia protease inhibitors (boceprevir and telaprevir) in combination with pegylated interferon and ribavirin and dual therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C genotype 1 without polymorphism Q80K, who had not responded to previous treatment. Global cost-effectiveness model was adapted to the Russian health care system. We calculated differences in direct medical costs between the antiviral therapy schemes, treatment of long-term complications of chronic hepatitis C and the costs of achieving sustained virological response (SVR) to treatment. The incremental cost-effectiveness ratio - additional cost per life year saved was calculated as well. Available published data and the tariffs of the Russian healthcare system were used for the calculations. Simeprevir was shown to be more effective than dual therapy with acceptable additional costs and more effective than boceprevir and telaprevir in the number of life years saved being less costly therapy option.
